Head-to-head
Tirzepatide vs AOD-9604
A field-by-field comparison of Tirzepatide and AOD-9604 drawn from the PeptideIndex database: mechanism, evidence grade, half-life, administration route, reported dosing, side effects, storage and legal status. Both are indexed as metabolic compounds, so the useful question is how they differ within that category.
Tirzepatide vs AOD-9604 at a glance
| Attribute | Tirzepatide | AOD-9604 |
|---|---|---|
| Category | Metabolic | Metabolic |
| Evidence grade | Strong | Limited |
| Also known as | Mounjaro, Zepbound | Anti-Obesity Drug 9604, hGH fragment 176-191 |
| Chain | 39 amino acid dual GIP/GLP-1 agonist | Fragment 176-191 of human growth hormone |
| Mechanism | Activates both GIP and GLP-1 receptors. The added GIP activity appears to improve insulin sensitivity and lipid handling while blunting some of the nausea associated with pure GLP-1 agonism. | Represents the lipolytic C-terminal region of hGH. In adipocytes it stimulates lipolysis and inhibits lipogenesis without binding the GH receptor, so IGF-1 and glucose remain unaffected. |
| Reported benefits | Up to ~21% mean weight loss at 15 mg in SURMOUNT-1 · Superior HbA1c reduction versus semaglutide in head-to-head trials · Improvements in sleep apnoea and blood pressure | Fat mobilisation without IGF-1 elevation · No reported impact on insulin sensitivity · Good tolerability profile in trials |
| Reported side effects | Nausea · Decreased appetite to the point of undereating · Diarrhoea · Rare pancreatitis | Generally well tolerated · Occasional injection-site reaction · Headache |
| Half-life | About 5 days | Under 30 minutes |
| Administration | Once-weekly subcutaneous injection | Subcutaneous injection, often fasted in the morning |
| Dosing overview | 2.5 mg weekly starting dose, escalating in 2.5 mg steps up to 15 mg | Commonly cited at 300 mcg daily, 5 days on / 2 off |
| Storage | Refrigerated pens; can be at room temperature for up to 21 days per label | Refrigerate reconstituted vials; powder stable at room temperature briefly |
| Legal status | FDA-approved and prescription-only. | Not approved as a drug; permitted as a food additive in some jurisdictions. |
Key differences between Tirzepatide and AOD-9604
Both are metabolic compounds
Tirzepatide and AOD-9604 are both indexed under metabolic, so they compete for the same use case rather than complementing each other. Tirzepatide: "A dual incretin agonist that has produced the largest weight reductions yet seen in obesity pharmacotherapy trials." AOD-9604: "A GH fragment marketed for fat loss without the blood-sugar effects of full growth hormone — though human trials have been underwhelming."
Mechanism of action
Tirzepatide: Activates both GIP and GLP-1 receptors. The added GIP activity appears to improve insulin sensitivity and lipid handling while blunting some of the nausea associated with pure GLP-1 agonism. AOD-9604: Represents the lipolytic C-terminal region of hGH. In adipocytes it stimulates lipolysis and inhibits lipogenesis without binding the GH receptor, so IGF-1 and glucose remain unaffected.
Evidence quality is not equal
Tirzepatide carries a Strong evidence grade and AOD-9604 a Limited grade on this index. The grade describes the quality of published human data, not how well a compound works — Tirzepatide has the better-documented record of the two, and claims made about AOD-9604 rest on thinner human evidence.
Half-life and dosing frequency
Tirzepatide is listed at about 5 days; AOD-9604 at under 30 minutes. That difference is what drives the reported schedules: 2.5 mg weekly starting dose, escalating in 2.5 mg steps up to 15 mg versus Commonly cited at 300 mcg daily, 5 days on / 2 off
Route of administration
Tirzepatide is administered by once-weekly subcutaneous injection. AOD-9604 is administered by subcutaneous injection, often fasted in the morning.
Legal and regulatory status differs
Tirzepatide: FDA-approved and prescription-only. AOD-9604: Not approved as a drug; permitted as a food additive in some jurisdictions. This is usually the most practical difference between two compounds, because it determines whether a supply chain is labelled and regulated at all.
Handling and storage
Tirzepatide is stored refrigerated pens; can be at room temperature for up to 21 days per label. AOD-9604 is stored refrigerate reconstituted vials; powder stable at room temperature briefly.
What Tirzepatide and AOD-9604 have in common
- Category: both listed as Metabolic
Each compound in brief
Tirzepatide
Metabolic · Strong evidence
A dual incretin agonist that has produced the largest weight reductions yet seen in obesity pharmacotherapy trials.
Considerations: Same muscle-preservation caveats as semaglutide · Slow titration is essential · High cost and periodic supply constraints
AOD-9604
Metabolic · Limited evidence
A GH fragment marketed for fat loss without the blood-sugar effects of full growth hormone — though human trials have been underwhelming.
Considerations: Phase IIb trials failed to beat placebo for weight loss at 12 weeks · Popular in clinics despite weak efficacy data · Best viewed as adjunctive, not a primary fat-loss tool
Related comparisons and reading
Every figure on this page is reproduced from the compound profiles in this database and reflects published literature and commonly reported protocols. It is educational information, not medical advice, and not a recommendation to use either compound. See the medical disclaimer.